Chris Gibson, Recursion’s head, cited the role small business grants played in helping Recursion grow its business.

We recently compiled a list of the Last Week’s Top 10 Stocks Post Double-Digit Gains. In this article, we are going to take a ...

Plus: A shift in bird flu strategy, a new vaccine for meningococcal disease, a new AI genomics model from Nvidia and more.

NVIDIA's continued investment in Recursion Pharmaceuticals strengthens the view that Recursion is a favored investment within ...

Recursion CEO Chris Gibson defends the NIH, investing $1 million into a pre-seed venture to encourage critical research and ...

If policymakers fail to act swiftly to restore medical research funding, then it’s up to those of us in the industry with the ...

A 13F itemizes the individual stocks money managers bought and sold during the most recent quarter. Investors can use these ...

That was the case for Recursion Pharmaceuticals, a now publicly traded company that applies artificial intelligence to drug discovery and development. With layoffs at the NIH underway and its ...

Recursion Pharmaceuticals RXRX is expected to report its fourth-quarter 2024 results soon. The Zacks Consensus Estimate for quarterly revenues in the to-be-reported quarter is pegged at $28.73 billion ...

Altitude Lab Fund will provide pre-seed funding for early-stage startups affected by changes to grant programs administered ...